IL6 and COVID-19: Since no molecular studies were available for CAM patients, we focused on studies featuring COVID-19 severity and selected nuclear factor erythroid 2-related factor 2 (NRF2), interleukin-6 (IL-6), and IL-15 as the candidate genes for this analysis (30, –, 33).